Rhythm Pharmaceuticals (RYTM) Income towards Parent Company (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Income towards Parent Company data on file, last reported at -$55.6 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 12.27% year-over-year to -$55.6 million in Q1 2026; TTM through Mar 2026 was -$202.6 million, a 20.04% decrease from a year earlier, with the FY2025 full-year figure at -$196.5 million, up 24.58% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$55.6 million, down from -$47.5 million in the prior quarter.
• Over the last five years, Income towards Parent Company for RYTM reached as high as -$32.3 million in Q2 2024 and fell as low as -$141.4 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$52.0 million across 5 years, with a median of -$46.7 million in 2023.
• Across the five-year window, Income towards Parent Company slumped 226.48% in 2022 and surged 64.97% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$42.5 million in 2022, then advanced by 2.02% to -$41.6 million in 2023, then fell by 4.07% to -$43.3 million in 2024, then retreated by 9.64% to -$47.5 million in 2025, then slipped by 17.03% to -$55.6 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$55.6 million in Q1 2026, -$47.5 million in Q4 2025, and -$52.9 million in Q3 2025.